Extração e caracterização qualitativa do óleo da polpa e amendoas de frutos de macaúba [Acrocomia aculeata (Jacq) Lodd. ex Mart] coletada na região de Botucatu - SP

The international energy situation indicates to the depletion of oil reserves in the short term. Brazil, considering its potential, has sought through public policy, encourage the study of alternative forms of energy. Many of these forms are based on sub-products and agricultural products, especially the ethanol industry for fuel purposes. Another alternative of vegetable origin, most recently discussed, would be the production of fuel oil called biodiesel. The study aimed to extract and measure the pulp oil production of macaúba palm [Acrocomia aculeata (Jacq) Lodd. ex Mart], collected in Botucatu (SP). In addition, the qualitative analysis of the pulp and almond oil are determined. The results showed low productivity in oils, compared to the reported for macauba natural populations of Minas Gerais. The qualitative analysis of the macauba pulp shows to be rich in long chain fatty acids, while the almond have significant amounts of lauric acid.

Manejo e conservação genética In Situ, Acrocomia aculeata (Jacq.) Lodd. Ex Mart. no pontal do Paranapanema

Pós-graduação em Agronomia - FEIS

Annus Iudaicus ex antiquitate Iudaica illustratus. Disputatio prima et generalior ex amplissimi philosophorum ordinis auctoritate D.XXVI. Mart.A.C.N. MDCCLXVI. publicae eruditorum censurae subiecta a Frider.

Mode of access: Internet.

O gênero Nectandra Rol. ex Rottb. (Lauraceae) no Estado do Paraná, Brasil

Nectandra Rol. ex Rottb. has 14 species in Paraná: Nectandra angustifolia (Schrader) Nees & Mart., N. cissiflora Nees, N. cuspidata Nees & Mart., N. grandiflora Nees & Mart., N. hihua (Ruiz & Pav.) Rohwer, N. lanceolata Nees & Mart., N. leucantha Nees & Mart., N. megapotamica (Sprengel) Mez, N. membranacea (Sw.) Griseb., N. nitidula Nees & Mart., N. oppositifolia Nees & Mart., N. paranaensis Coe-Teixeira, N. puberula (Schott) Nees and N. reticulata (Ruiz & Pav.) Mez. We present an identification key and species descriptions, as well as illustrations and data on phenology and geographic distribution. N. hihua is cited for the first time in Paraná State.

Nectandra Rol. ex Rottb. (Lauraceae) no Mato Grosso do Sul, Brasil

O trabalho apresenta o estudo taxonômico das espécies do gênero Nectandra no Mato Grosso do Sul, Brasil. Baseados na análise morfológica dos espécimes coletados em diferentes regiões do Estado são confirmados oito espécies de Nectandra: N. amazonum Nees, N. cissiflora Nees, N. cuspidata Nees, N. falcifolia (Nees) J.A. Castigl. ex Mart. Crov. & Piccinini, N. gardneri Meisn., N. hihua (Ruiz & Pav.) Rohwer, N. megapotamica (Spreng.) Mez e N. psammophila Nees. É fornecida uma chave de identificação para as espécies e apresentados descrições morfológicas, dados de distribuição geográfica, habitat, aspectos fenológicos, comentários taxonômicos e ilustrações para cada espécie.

Biologia de Rolepa unimoda (Dognin,1923) (Lepidoptera, Lymantriidae) em folhas de Tabebuia avellanedae Lor. ex-griseb (Bignoniaceae) e observações sobre inimigos naturais

Este trabalho trata do estudo da biologia de Rolepa unimoda (Dognin,1923) (Lepidoptera, Lymantriidae), cujas lagartas são desfolhadoras em plantios ornamentais de Tabebuia avellanedae Lor. ex-Griseb (Bignoniaceae). Ataca também T. caraiba (Mart.) Burm. Os insetos foram criados em condições de laboratório (Temperatura 27±2°C; UR: 70 ± 15%, Fotoperíodo de 12 h), na Seção de Entomologia do Centro de Ciências Agrárias da Fundação Universidade Federal de Mato Grosso, em Cuiabá, MT. Foram estudados os seguintes parâmetros: período e viabilidade das fases de ovos,lagarta, pré-pupa e pupa; número e duração dos ínstares larvais e consumo foliar da fase de lagarta; longevidade dos adultos e proporção quanto ao sexo; inimigos naturais; plantas hospedeiras e ocorrência do inseto nos Estados de Mato Grosso e Mato Grosso do Sul.

MART-1 peptide vaccination plus IMP321 (LAG-3Ig fusion protein) in patients receiving autologous PBMCs after lymphodepletion: results of a Phase I trial.

BACKGROUND: Immunotherapy offers a promising novel approach for the treatment of cancer and both adoptive T-cell transfer and immune modulation lead to regression of advanced melanoma. However, the potential synergy between these two strategies remains unclear. METHODS: We investigated in 12 patients with advanced stage IV melanoma the effect of multiple MART-1 analog peptide vaccinations with (n = 6) or without (n = 6) IMP321 (LAG-3Ig fusion protein) as an adjuvant in combination with lymphodepleting chemotherapy and adoptive transfer of autologous PBMCs at day (D) 0 (Trial registration No: NCT00324623). All patients were selected on the basis of ex vivo detectable MART-1-specific CD8 T-cell responses and immunized at D0, 8, 15, 22, 28, 52, and 74 post-reinfusion. RESULTS: After immunization, a significant expansion of MART-1-specific CD8 T cells was measured in 83% (n = 5/6) and 17% (n = 1/6) of patients from the IMP321 and control groups, respectively (P < 0.02). Compared to the control group, the mean fold increase of MART-1-specific CD8 T cells in the IMP321 group was respectively >2-, >4- and >6-fold higher at D15, D30 and D60 (P < 0.02). Long-lasting MART-1-specific CD8 T-cell responses were significantly associated with IMP321 (P < 0.02). At the peak of the response, MART-1-specific CD8 T cells contained higher proportions of effector (CCR7⁻ CD45RA⁺/⁻) cells in the IMP321 group (P < 0.02) and showed no sign of exhaustion (i.e. were mostly PD1⁻CD160⁻TIM3⁻LAG3⁻2B4⁺/⁻). Moreover, IMP321 was associated with a significantly reduced expansion of regulatory T cells (P < 0.04); consistently, we observed a negative correlation between the relative expansion of MART-1-specific CD8 T cells and of regulatory T cells. Finally, although there were no confirmed responses as per RECIST criteria, a transient, 30-day partial response was observed in a patient from the IMP321 group. CONCLUSIONS: Vaccination with IMP321 as an adjuvant in combination with lymphodepleting chemotherapy and adoptive transfer of autologous PBMCs induced more robust and durable cellular antitumor immune responses, supporting further development of IMP321 as an adjuvant for future immunotherapeutic strategies.

Ex vivo detectable activation of Melan-A-specific T cells correlating with inflammatory skin reactions in melanoma patients vaccinated with peptides in IFA.

The purpose of this study was to test melanoma vaccines consisting of peptides and immunological adjuvants for optimal immunogenicity and to evaluate laboratory immune monitoring for in vivo relevance. Forty-nine HLA-A2 positive patients with Melan-A positive melanoma were repeatedly vaccinated with Melan-A peptide, with or without immune adjuvant AS02B (QS21 and MPL) or IFA. Peptide-specific CD8 T cells in PBLs were analyzed ex vivo using fluorescent HLA-A2/Melan-A multimers and IFN-gamma ELISPOT assays. The vaccines were well tolerated. In vivo expansion of Melan-A-specific CD8 T cells was observed in 13 patients (1/12 after vaccination with peptide in AS02B and 12/17 after vaccination with peptide in IFA). The T cells produced IFN-gamma and downregulated CD45RA and CD28. T-cell responses correlated with inflammatory skin reactions at vaccine injection sites (P < 0.001) and with DTH reaction to Melan-A peptide (P < 0.01). Twenty-six of 32 evaluable patients showed progressive disease, whereas 4 patients had stable disease. The two patients with the strongest Melan-A-specific T-cell responses experienced regression of metastases in skin, lymph nodes, and lung. We conclude that repeated vaccination with Melan-A peptide in IFA frequently leads to sustained responses of specific CD8 T cells that are detectable ex vivo and correlate with inflammatory skin reactions.

Vaccination of melanoma patients with Melan-A/Mart-1 peptide and Klebsiella outer membrane protein p40 as an adjuvant.

Toll-like receptor ligands are potentially useful adjuvants for the development of clinical T cell vaccination. Here we investigated the novel Toll-like receptor2 ligand P40, the outer membrane protein A derived from Klebsiella pneumoniae. Seventeen human leukocyte antigen-A*0201 positive stage III/IV melanoma patients were vaccinated with P40 and Melan-A/Mart-1 peptide subcutaneously in monthly intervals. Adverse reactions were mild-to-moderate. Fourteen patients received at least 8 vaccinations and were thus evaluable for clinical tumor and immune responses. Seven patients experienced progressive disease, whereas 2 patients had stable disease throughout the trial period, 1 of them with regression of multiple skin metastases. The remaining 5 patients had no measurable disease. Melan-A/Mart-1 specific CD8 T cells were analyzed ex vivo, with positive results in 6 of 14 evaluable patients. Increased percentages of T cells were found in three patients, memory/effector T cell differentiation in 4 patients, and a positive interferon-gamma Elispot assay in 1 patient. Antibody responses to P40 were observed in all patients. We conclude that vaccination with peptide and P40 was feasible and induced ex vivo detectable tumor antigen specific T cell responses in 6 of 14 patients with advanced melanoma.

Ex vivo analysis of human antigen-specific CD8+ T-cell responses: quality assessment of fluorescent HLA-A2 multimer and interferon-gamma ELISPOT assays for patient immune monitoring.

The authors developed a standardized approach for immune monitoring of antigen-specific CD8+ T cells within peripheral blood lymphocytes (PBLs) that combines direct ex vivo analysis of Melan-A/MART-1 and influenza-specific CD8+ T cells with HLA-A2/peptide multimers and interferon-gamma ELISPOT assays. Here the authors assessed the quality of results obtained with 180 PBLs from healthy donors and melanoma patients. Reproducibility of the multimer assay was good (average of 15% variation). In the absence of in vivo antigen-specific T-cell responses, physiologic fluctuations of multimer-positive T cells was low, with variation coefficients of 20% for Melan-A and 28% for influenza-specific T cells. In contrast, patients with vaccination-induced T-cell responses had significantly increased T-cell frequencies clearly exceeding physiologic fluctuations. Comparable results were obtained with ELISPOT assays. In conclusion, this approach is well suited to assess T-cell responses as biologic endpoints in clinical vaccine studies.

Ex vivo characterization of allo-MHC-restricted T cells specific for a single MHC-peptide complex.

Alloreactive T cells are thought to be a potentially rich source of high-avidity T cells with therapeutic potential since tolerance to self-Ags is restricted to self-MHC recognition. Given the particularly high frequency of alloreactive T cells in the peripheral immune system, we used numerous MHC class I multimers to directly visualize and isolate viral and tumor Ag-specific alloreactive CD8 T cells. In fact, all but one specificities screened were undetectable in ex vivo labeling. In this study, we report the occurrence of CD8 T cells specifically labeled with allo-HLA-A*0201/Melan-A/MART-1(26-35) multimers at frequencies that are in the range of 10(-4) CD8 T cells and are thus detectable ex vivo by flow cytometry. We report the thymic generation and shaping of tumor Ag-specific, alloreactive T cells as well as their fate once seeded in the periphery. We show that these cells resemble their counterparts in HLA-A*0201-positive individuals, based on their structural and functional attributes.

Ex vivo detectable human CD8 T-cell responses to cancer-testis antigens.

Clinical trials have shown that strong tumor antigen-specific CD8 T-cell responses are difficult to induce but can be achieved for T-cells specific for melanoma differentiation antigens, upon repetitive vaccination with stable emulsions prepared with synthetic peptides and incomplete Freund's adjuvant. Here, we show in four melanoma patients that ex vivo detectable T-cells and thus strong T-cell responses can also be induced against the more universal cancer-testis antigens NY-ESO-1 and Mage-A10. Interestingly, all patients had ex vivo detectable T-cell responses against multiple antigens after serial vaccinations with three peptides emulsified in incomplete Freund's adjuvant. Antigen-specific T-cells displayed an activated phenotype and secreted IFNgamma. The robust immune responses provide a solid basis for further development of human T-cell vaccination.

Humana felicitas ex nexu veritatum, in theoria & praxi

Invocatio: Duc me, sine me sine te, Deus optime, duci. Nam duce me pereo; te duce saluus ero.

Themata nonnulla ex amoenissimo physices viridario deprompta, exhibens

Variantti B.

Wal-Mart et la liberté d'association : un recul des libertés politiques au Québec?

Le 2 avril 2004, le magasin Wal-Mart de Jonquière devient le premier établissement de cette multinationale à se syndiquer en Amérique du Nord. Moins d'un an plus tard, le 9 février 2005, la compagnie Wal-Mart annonce la fermeture de son magasin de Jonquière, le jour même où le ministre du Travail nommait un arbitre en vertu du Code du travail pour fixer la première convention collective. Certains des ex-employés du magasin de Jonquière décident alors de porter plainte à la Commission des relations de travail en vertu des articles 15 à 17 du Code du travail du Québec (L.R.Q. ch. C-27), arguant la prise de mesures illégales par Wal-Mart en représailles à l'exercice d'activités syndicales. En compensation, les salariés demandent d'être réintégrés dans leurs emplois.